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We present evidence that the HIV-1 Tat protein and the RNA-dependent cellular protein kinase, PKR, interact with each
other both in vitro and in vivo. Using GST fusion chromatography, we demonstrate that PKR, interacts directly with the HIV-
1 Tat protein. The region in Tat sufficient for binding PKR maps within amino acids 20 to 72. In in vitro assays, the two-exon
form of Tat (Tat 86) was phosphorylated by PKR, while the one exon form of Tat (Tat 72) inhibited PKR autophosphorylation and
substrate phosphorylation. The ability of Tat to interact with PKR was demonstrated in both yeast and mammalian cells.
Expression of PKR in yeast results in a growth suppressor phenotype which was reversed by coexpression of a one exon
form of Tat. Expression of Tat 72 in HeLa cells resulted in direct interaction with PKR as detected by coimmunprecipitation
with a Tat antibody. Tat and PKR also form a coimmunoprecipitable complex in cell-free extracts prepared from productively
infected T lymphocytes. The interaction of Tat with PKR provides a potential mechanism by which HIV could suppress the
interferon system. q 1995 Academic Press, Inc.
INTRODUCTION protein kinase, PKR ( for reviews see Hovanessian, 1989;
Samuel, 1991). PKR is found in most cell types and is
One of the intriguing features of HIV infection of hu- induced 5- to 10-fold upon exposure to interferon (Gala-
mans is the presence of increasing serum levels of the bru and Hovanessian, 1985; Samuel, 1991). It is activated
antiviral agent, interferon (IFN), as the disease prog- by low concentrations of double-stranded (ds) RNA, re-
resses (Read et al., 1985). Increased levels of the inter- sulting in autophosphorylation of several serine residues
feron-induced enzyme 2–5A synthetase, which plays a on the kinase molecule, while high concentrations of
role in the antiviral effects of interferon (Rysiecki et al., dsRNA are known to inhibit PKR activation (Galabru and
1990), have also been correlated with disease progres- Hovanessian, 1987; Galabru et al., 1989). Once activated,
sion (Read et al., 1985). Thus HIV appears to have PKR is then able to phosphorylate its major substrate,
evolved mechanisms for overcoming inhibition by inter- the a subunit of eukaryotic initiation factor 2 (eIF2a) (Ho-
feron. Paradoxically, treatment of many cell types, includ- vanessian, 1989). This results in rapid inhibition of protein
ing peripheral blood lymphocytes, monocytes, macro- synthesis due to the sequestering and inactivation of
phages, and T cells, with IFN has been shown to inhibit the guanine nucleotide exchange factor, eIF2B, by the
HIV type 1 (HIV-1) infection (Dolei et al., 1986; Gendelman phosphorylated eIF2a (Safer, 1983; Hershey, 1989).
et al., 1990; Hartshorn et al., 1987; Ho et al., 1985; Korn- The gene encoding PKR has been cloned and charac-
bluh et al., 1989, 1990; Poli et al., 1989; Yamada et al., terized (Meurs et al., 1990). PKR contains all of the protein
1988; Yamamoto et al., 1986), although the molecular kinase subdomains within the C-terminal region, while
mechanisms involved appear to differ depending upon the N-terminal region has been shown to be important
cell type. for the binding of dsRNA (Barber et al., 1991; Chong et
IFN treatment of mammalian cells results in the estab- al., 1992; Feng et al., 1992; Katze et al., 1991; Patel and
lishment of an antiviral state mediated at least in part by Sen, 1992). PKR shares homology at the C-terminal end
the interferon-induced, double-stranded RNA-activated with two other eukaryotic eIF2a kinases, the heme-con-
trolled repressor and GCN2. Alignment of these se-
quences indicates a common insert region between ki-1 To whom correspondence and reprint requests should be ad-
nase subdomains IV and V which may define a commondressed at Department of Cancer Biology—NN10, The Cleveland
eIF2a binding site (Chong et al., 1992; Ramirez et al.,Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195. Fax:
(216) 445-6269. E-mail: williab@cesmtp.ccf.org. 1992). PKR has been expressed in Saccharomyces cere-
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visiae, resulting in a growth suppression phenotype due was reverted by coexpression of single-exon Tat, and in
productively infected T lymphocytes.to the phosphorylation of yeast eIFa (Chong et al., 1992;
Dever et al., 1992, 1993). This slow-growth phenotype
can be reversed by the coexpression of either the N- MATERIALS AND METHODS
terminal half of PKR or mutant yeast eIF2a (Chong et al.,
1992). In accord with this growth suppressor activity in Plasmids and proteins. pGEX-PKR was created by in-
serting the 2-kb HindIII cDNA fragment (Meurs et al.,yeast, expression of inactive kinase mutants in NIH3T3
cells resulted in cell transformation and tumor formation 1990) into the SmaI site of pGEX2T. pGEX-6M was simi-
larly cloned, but using the Lys296 –Arg mutant previouslyin a nude mouse assay (Koromilas et al., 1992, Meurs et
al., 1993). described (Chong et al., 1992). To create pLTR3T4hyg,
the SFFV LTR of pSFSVn-LC7 (Ballhausen et al., 1988)HIV transactivation-responsive RNA has been shown
to activate PKR in vitro due to its extensive secondary was removed by EcoRI–SacI digestion and replaced by
blunt-end ligation with a functional HIV-1 3* LTR (ntsstructure (Edery et al., 1989; Maitra et al., 1994; Roy et
al., 1991; SenGupta and Silverman, 1989), although one 8443–9162 of HIV isolate HXB2); the neo gene of the
resultant plasmid was removed by complete HindIII andreport suggests an inhibitory activity (Gunnery et al.,
1990). Previous work has suggested that HIV infection partial BamHI digestion and replaced by the 2.2-kb Hin-
dIII– BamHI fragment of pGEMSV2hyg (Siderovski et al.,reduces the cellular level of PKR (Roy et al., 1990). This
reduction was also observed in HeLa cells stably ex- 1992), containing the hyg gene and SV40 polyadenylation
signal. Plasmids pMAMTat86, pMAMTat72, and pMAM-pressing normal HIV-1 Tat but not a Tat mutant. However,
the mechanism by which continual expression of Tat Tat72AS contain the 286-bp XhoI–SalI cDNA fragment of
pGEMSV2Tatwt (Siderovski et al., 1992) and the 1.3-kbdecreases PKR levels was left unresolved. Tat stimulates
efficient HIV gene expression by interacting with the SalI–PvuII fragment of Tat exon 1 (nts 5342–6631 of
HIV isolate HXB2) in sense and antisense orientation,transactivation-responsive (TAR) region found in all HIV
mRNAs, and hence is essential for HIV replication (Arya respectively, each cloned within the SalI site of pMAM-
neo (Clontech, Palo Alto, CA). The plasmid yex4Tat(1–et al., 1985; Drysdale and Pavlakis, 1991; Huang et al.,
1994; Rosen, 1991). Two forms of Tat are synthesized 67) was created by inserting the 240-bp SalI–HindIII frag-
ment from the HIV-1 genomic clone pNL43 in the SalI–during HIV-1 infection, the two-exon form (86 amino acids
for LAI/Bru HIV 1 derivatives, approximately 101 amino HindIII of yeast expression vector pEMBLyex4. This plas-
mid contains the URA3 gene and the GAL10-CYC1 hybridacids for all others) made in the absence of HIV Rev
activity (early expression) and a single exon, 72-amino- promotor and codes for the first 67 amino acids of the
HIV Tat gene. Plasmid yex4Tat86 was created by in-acid protein that appears in the presence of Rev activity
(late expression) (Malim and Cullen, 1991). Both forms serting the 290-bp BglII–SalI fragment of Tat cDNA M910
(Siderovski et al., 1992) into the BamHI–SalI site of pEM-of Tat (Tat 72 and Tat 86–101) are fully functional in
transactivating the HIV LTR (long terminal repeat) (So- BLyex4. Plasmid 86H has been described elsewhere
(Chong et al., 1992). It contains the HIS3 gene and thedroski et al., 1985; Tiley et al., 1990; Weeks et al., 1990).
Tat also interacts with cellular proteins such as the Tat human PKR gene under the control of the GAL10-CYC1
hybrid promotor. Tat 72 was synthesized by Dr. Clark-binding protein, TBP-1 (Nelbock et al., 1990), MSS-1 (Shi-
buya et al., 1992), and Sp1 (Jeang et al., 1993a,b), al- Lewis and corresponds to the amino acid residues 1 to
72 of the LAI/BRU isolate sequence. Recombinant Tat 86though the functional implications of these interactions
remain to be determined. Tat may also play functional (product of the first and the second exons of the tat gene)
and recombinant Rev proteins were from American Bio-roles in addition to transcription (Huang et al., 1994).
As PKR has previously been shown to be activated by Technologies Inc. and were provided through the AIDS
Research and Reference Reagent Program, Division Re-HIV TAR RNA in vitro (Edery et al., 1989; Maitra et al.,
1994; Roy et al., 1991; SenGupta and Silverman, 1989) agent Program, of AIDS, NIAID, NIH. SDS–PAGE analy-
sis and visualization by silver staining indicated that Tatand the expression of Tat protein correlated with a reduc-
tion in PKR activity (Roy et al., 1990), we investigated the 86 and Tat 72 proteins were greater than 95% pure. His-
tones H2A and H3 were from Sigma.possibility that Tat was interacting directly with PKR. Here
we show that Tat binds directly to PKR. Interestingly, Cell lines. HeLa S3 cells (ATCC CCL 2.2) were ob-
tained from the American Type Culture Collection (Rock-while Tat 72 inhibited the activation of PKR, Tat 86 was
phosphorylated by PKR. Preincubation of PKR with eIF2 ville, MD). All HeLa cell lines were maintained at 377C
and 5% CO2 in Dulbecco’s modified Eagle’s medium sup-blocked Tat protein binding and the inhibition of PKR
activity by Tat 72. The interaction was also manifested plemented with 10% fetal calf serum (FCS), 100 mg/ml
penicillin, 100 mg/ml streptomycin, and appropriate G418in HeLa cells where functional Tat 72 bound cellular PKR,
as indicated by coimmunoprecipitation. In vivo interac- and hygromycin-B concentrations (see below). The cell
line HeLa LTRT4 was obtained by calcium-phosphate-tion could also be demonstrated in Saccharomyces cere-
visiae, where the PKR-mediated repression of growth mediated transfection of HeLa S3 with pLTRL3T4hyg and
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subsequent hygromycin-B selection (300 g/ml). HeLa cell sively (more than 20 column volumes) with buffer (20 mM
HEPES, pH 7.9 [KOH], 1 mM MgCl2 , 17% glycerol, 2 mMlines LTRT4/Tat86, LTRT4/Tat72, and LTRT4/Tat72AS
were created by liposome-mediated transformation DTT) containing 0.1 M KCl (wash). Subsequent to wash-
ing, the sepharose beads were eluted stepwise with(Felgner et al., 1987) of HeLa LTRT4 with pMAMTat86,
pMAMTat72, and pMAMTat72AS, respectively, and sub- buffer containing 0.25 M KCl and then 0.5 M KCl. Eluates
were desalted and concentrated using a 10,000 MW cut-sequent selection in medium containing 700 mg/ml G418
(active) and 300 mg/ml hygromycin-B. MT-2 cells infected off microconcentration tube (Amicon) resolved by SDS–
PAGE.with HIV-1 (NL4–3) were cultured as described pre-
viously (Jeang et al., 1993a). Western blotting. Proteins were separated by SDS–
PAGE and blotted to polyvinyl difloride membrane (Im-In vitro autophosphorylation assay. PKR was purified
from interferon-treated Daudi cells using a specific mobilon-P, Millipore Corp.) according to the manufactur-
ers instructions. Blots were reacted with Tat polyclonalmonoclonal antibody (MAb 71/10) with protein G Sepha-
rose and assayed for protein kinase activity as previously antibody (705, provided by the AIDS Research and Refer-
ence Reagent Program, Division of AIDS, NIAID, NIH,described (Hovanessian et al., 1987). Briefly, for the acti-
vation of PKR, immune complex preparations were incu- from Dr. Bryan Cullen) or PKR polyclonal or monoclonal
antibody and detection was performed using a peroxi-bated in buffer C (20 mM HEPES, pH 7.5, 50 mM potas-
sium chloride, 5 mM 2-mercaptoethanol, 1.5 mM magne- dase-labeled secondary antibody and enhanced chemi-
luminescence (ECL) (Amersham).sium acetate, and 1.5 mM manganese chloride)
containing poly(I):poly(C) (1 mg/ml) and 2 mM [g-32P]ATP Expression of HIV-1 Tat in Saccharomyces cerevisiae.
Plasmids were transformed into a yeast strain W303a(50 Ci/mmol) at 307C for 15 min. For the phosphorylation
of exogenous substrates, after PKR phosphorylation the (MATa, can1-100, his3-11,15, leu2-3, 112, trp1-1, ura3-1,
ade2-1) already containing PKR (86H) under the GAL10-samples were washed before incubation (15 min, 307C)
in buffer C containing [g-32P]ATP (as above) and the ex- CYC-1 promoter on the centromeric CEN/ARS vector
pRS313, as previously described (Chong et al., 1992).ogenous substrate (eIF2, Tat 86, or histone H2A). Eukary-
otic initiation factor 2 purified to 85% homogeneity was Expression of PKR and Tat was induced by growth on
2% galactose plates. All plasmids were maintained bya gift from Dr. William Merrick. Reactions were stopped
by the addition of twofold concentrated electrophoresis selection based on the prototrophic markers contained
within each plasmid.buffer and the samples were analyzed by 10 or 15% SDS –
PAGE. 32P-labeled PKR, H2A, and Tat 86 were visualized Yeast protein preparation. Yeast strains were grown
in minimal medium (0.67% Bacto yeast nitrogen baseby autoradiography.
Expression of glutathione-S-transferase–PKR fusion without amino acids, 0.1% glucose, and tryptophan and
leucine added to 20 mg/ml) at 307C to an OD600 of 1.0.protein. The plasmid pGST–PKR or pGST–6M were
transformed into the Escherichia coli strain DH5a. Over- Following extensive washing the cells were resus-
pended in minimal medium containing tryptophan andnight cultures (50 ml) of uninduced cells were harvested
by centrifugation at 5000 g and resuspended in ice-cold leucine at 20 mg/ml with 2% galactose as the carbon
source and the incubation was continued at 307C. CellsPBS. Cells were lysed by sonication (3 pulses of 15 sec
at 20,000 cycles) and centrifuged at 12,000 g before the were harvested after 24 hr, washed in ice-cold water,
and resuspended in 1 ml of disruption buffer (20 mMaddition of 100 ml glutathione–Sepharose beads (Phar-
macia). Cell extracts were incubated at 47C for 15 min Tris – HCl, pH 8, 10 mM MgCl2 , 1 mM EDTA, 5% glycerol,
1 mM DTT, 0.3 M ammonium acetate, and 1 mM PMSF).and the beads washed five times with ice-cold PBS and
stored at 0707C. GST – Tat or GST–Tax fusion proteins The cells were disrupted by vortexing five times for 1
min in the presence of 1/2 volume of glass beads andwere similarly prepared.
Protein binding assays between PKR and HIV-1 Tat. the supernatant was decanted and centrifuged for 60
min at 12,000 g.For these assays glutathione beads were pretreated with
0.5% skim milk in buffer C prior to PKR purification. Bind- Immunofluorescence analysis. Adherent HeLa cell cul-
tures were collected in calcium- and magnesium-freeing assays were performed by washing the GST–PKR/
glutathione–Sepharose beads twice in buffer C followed phosphate-buffered saline (PBS) containing 0.6 mM
EDTA, stained with phycoerythrin-conjugated anti-L3T4by the addition of 1 mg of Tat 72 protein. Incubation was
continued on ice for 30 min before extensive washing monoclonal antibody (Becton–Dickinson, San Jose, CA)
for 1 hr at 47C in 100 ml PBS / 2.5% FCS, washed withwith buffer C supplemented with 0.5% NP 40. The beads
were treated with SDS–PAGE buffer and boiled for 3 min cold PBS, and analyzed by single-color flow cytometry
on a FACScan (Becton–Dickinson).and the eluted proteins separated by SDS–PAGE. GST
(Pharmacia), GST–Tat (amino acids 1 to 101) fusion or Preparation of HeLa cell extracts. Cell extracts from
confluent 100-mm plates were prepared as previouslyGST–Tax fusion proteins were bound to glutathione –
Sepharose 4B beads. The protein–beads were reacted described (Hovanessian et al., 1987) except that Buffer I
(20 mM Tris–HCl, pH 7.6, 50 mM KCl, 400 mM NaCl, 1separately with cell extracts and then washed exten-
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FIG. 1. HIV-1 Tat 86 is phosphorylated specifically by activated PKR. Monoclonal antibody-bound PKR was first activated (1 mg per sample) before
the addition of Tat 86 (A) or Tat 72 (B) at different concentrations : 0, 0.05, 0.1, 0.2, 0.4, and 1 mg in lanes 1–6, respectively. The arrow indicates
the position of Tat 86. In (C) PKR preparations were first activated in the absence or presence (0// lanes) of poly(I):poly(C) before the addition of
different substrates : Tat 86 (1 mg), Rev (1 mg), and histone H2A (5 mg). Only the section of the gel corresponding to the positions of Tat 86 (14
kDa), Rev (18 kDa), and histone H2A (15 kDa) is presented. Note: B was overexposed to show the lack of phosphorylation of Tat 72.
mM EDTA, 1% Triton X-100, 20% glycerol, and 5 mM 2- vanessian, 1987). Activation requires the binding of
dsRNA to PKR molecules or, alternatively, single-mercaptoethanol) contained 40 mM NaCl and 10 mg/ml
leupeptin. Equal amounts of total protein were reacted stranded RNA molecules presenting internal dsRNA
structures such as HIV TAR RNA (Galabru et al., 1989;with a monoclonal antibody to PKR (71/10) in the low
salt Buffer I for 16 hr before the addition of protein G – Roy et al., 1991). Once PKR becomes autophosphorylated
it is no longer dependent on its activator and can catalyzeSepharose. Incubation was continued for 60 min before
the Sepharose beads were washed three times in Buffer phosphorylation of exogenous substrates such as the a
subunit of eIF2, histone H2A, or IkB (Galabru and Ho-II (20 mM Tris–HCl, pH 7.6, 100 mM KCl, 0.1 mM EDTA,
and 20% glycerol) and twice in Buffer III (Buffer II plus 2 vanessian, 1987; Kumar et al., 1994).
Since Tat is a basic protein and has potential PKRmM MnCl2 and 2 mM MgCl2). The amount of PKR ex-
tracted was determined by Western blotting and equal phosphorylation sites within its sequence, we analyzed
the capacity of activated PKR (i.e., autophosphorylated)amounts of kinase were used in kinase assays.
Coimmunoprecitation of Tat and PKR. HeLa cell ex- to catalyze phosphorylation of one- and two-exon forms
of Tat. Only the two-exon form (Tat 86) was found to betracts were prepared as described above using low salt
Buffer I (Buffer I with 40 mM NaCl). Antibodies were phosphorylated by PKR (Figs. 1A and 1B). The extent of
phosphorylation of both Tat 86 and histone H2A wasadded to 1 mg of cell extracts at a 1/1500 dilution and
incubated at 47C for 3 hr before the addition of protein highly dependent on the prior activation of PKR by
dsRNA, confirming that Tat 86 phosphorylation was medi-A–Sepharose (Pharmacia) and the incubation was con-
tinued overnight. The immunocomplexes were washed ated through PKR (Fig. 1C). Indeed, we have previously
demonstrated that the degree of phosphorylation of his-three times in low salt Buffer I, resuspended in SDS –
PAGE buffer, subjected to SDS–PAGE, and Western blot- tone H2A is directly correlated to the degree of activation
of PKR (Galabru and Hovanessian, 1987). As a furtherted as described above. PKR was detected using a poly-
clonal antibody to PKR provided by Drs. Michael Katze control, the rev gene product Rev, a basic protein that
appears to be phosphorylated during HIV infection (Ro-and Glenn Barber. Coimmunoprecipitation of Tat and
PKR from cell-free extracts of MT-2 cells infected with sen, 1991), was used in phosphorylation assays. How-
ever, Rev was not able to be efficiently phosphorylatedHIV-1 (NL4-3) was performed on cells harvested at a time
when more than 70% showed light microscopy-visible by activated PKR, indicating specificity for the phosphory-
lation of Tat 86 by PKR.cytopathic effects from infection. The immunocomplexes
were analyzed as described (Jeang et al., 1993a). The observation that Tat 86 was specifically phosphor-
ylated by PKR suggested the presence of a Tat recogni-
tion site within PKR. Therefore the effect of Tat 72 on theRESULTS
two kinase functions of PKR: (1) autophosphorylation and
(2) phosphorylation of the substrates Tat 86 and histoneHIV-1 Tat 86, but not Tat 72, is phosphorylated by PKR
H2A, was investigated (Fig. 2). PKR samples (1 mg perin vitro. PKR is a serine/threonine kinase that manifests
assay) were mixed with different amounts of Tat 72 be-two distinct protein kinase activities (Hovanessian, 1989),
fore being activated with dsRNA, and the level of kinaseone for PKR activation through autophosphorylation and
autophosphorylation was determined. Almost completethe other for phosphorylation of exogenous substrates
which are generally basic proteins (Galabru and Ho- inhibition of autophosphorylation was observed at 0.2 mg
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FIG. 2. Tat 72 inhibits the functioning of PKR. (A) Inhibition of PKR autophosphorylation by Tat 72. Monoclonal antibody-bound PKR (1 mg) was
first incubated (5 min, 207C) in the absence (0) or presence of histone H3 (5 mg), Rev (1 mg), or Tat 72 (0.1, 0.2, or 0.4 mg) before assay of PKR
phosphorylation (see Materials and Methods). (B) Inhibition of PKR-catalyzed Tat 86 phosphorylation by Tat 72. Activated PKR preparations were
washed in buffer C and incubated (5 min, 207C) in the absence or presence of Tat 72 (0.1, 0.2, or 0.4 mg as indicated). The different samples were
then assayed for the phosphorylation of Tat 86 (0.2 mg). (C) Inhibition of PKR-catalyzed histone H2A phosphorylation by Tat 72. Experimental
procedure was as in B but histone H2A was used instead of Tat 86.
of Tat 72, a concentration that represents equal molar sion (Figs. 4A and 4B). (Tax, which has no sequence
relatedness to Tat, is the 40-kDa trans-activator proteinratios of PKR and Tat. The observed inhibition did not
appear to be a general property of basic proteins since from HTLV-I.) Cell extracts were equilibrated with each
affinity column matrix; bound proteins were then elutedneither Rev nor histone H3 caused inhibition of PKR auto-
phosphorylation (Fig. 2A). To test whether Tat 72 could with increasing concentrations of KCl and analyzed us-
ing either a monoclonal (Fig. 4B) or a polyclonal (Fig.inhibit kinase substrate phosphorylation, PKR was preac-
tivated by dsRNA prior to being mixed with Tat 72 and 4A) anti-PKR serum. Both sera detected PKR in the GST –
Tat 0.25 M KCl eluate (Fig. 4A, lane 8; Fig. 4B, lane 10),phosphorylation of the exogenous substrates Tat 86 (0.2
mg) or histone H2A (5 mg) was monitored. The addition while no PKR was found in the GST alone or in GST –
Tax samples (Figs. 4A and 4B).of 0.2 mg of Tat 72 resulted in a dramatic reduction in
substrate phosphorylation (Figs. 2B and 2C), thus indicat- To define further the region within Tat sufficient for
interaction with PKR, deleted versions of the first codinging that Tat 72 is likely interacting with the same sub-
strate recognition site as Tat 86 within PKR. exon of Tat were expressed as GST fusions (Fig. 4). In
our experience, the laboratory strain of HIV-1 (i.e., HSB2HIV-1 Tat binds directly to PKR. To further investigate
the interaction between Tat and PKR, protein binding or NL4-3) that expresses the 1–86 amino acids of Tat
(Myers et al., 1994) and a molecularly engineered versionassays were performed. Monoclonal antibody-bound
PKR, attached to protein G–Sepharose beads, was incu- of HIV-1 (NL4-3) that expresses exclusively the 1- to 72-
amino-acid first coding exon of Tat (Chang, Neuvet, andbated with different amounts of Tat 72 before being
washed extensively (in order to eliminate unbound pro-
tein). Equal aliquots of each sample were then assayed
by immunoblotting, to reveal the presence of equal
amounts of PKR protein, and by autophosphorylation to
show the activation of PKR (Fig. 3). The phosphorylation
of PKR was reduced substantially in relation to the
amount of Tat 72 added during the preincubation period.
As different samples were washed extensively after pre-
incubation, the inhibition of PKR autophosphorylation
was most likely due to binding of Tat 72.
The direct interaction of Tat with PKR was confirmed
by determining the fragments of Tat sufficient for medi-
FIG. 3. Tat 72 binds to PKR and inhibits its activation. Monoclonalating interactions with PKR. This was achieved by ana-
antibody-bound PKR was first incubated (10 min, 207C) in buffer Clyzing for protein – protein complex formation using
containing different amounts of Tat 72 (as indicated). These prepara-GST – Tat fusion-polypeptide chromatography. The bind-
tions were then washed extensively in buffer C and separated into two
ing of PKR to the GST – Tat column (Tat amino acids 1- equal aliquots for the assay of PKR phosphorylation (A) and absolute
101) was compared to the binding of PKR to similar levels of PKR protein following immunoblotting using monoclonal anti-
body 71/10 and 125I-labeled goat anti-mouse immunoglobulins (B).columns made from either GST alone or GST – Tax fu-
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FIG. 4. (A,B,C) Retention of PKR in a GST–Tat protein column. GST (Pharmacia), GST–Tat (amino acids 1 to 101) fusion, or GST–Tax fusion
proteins were bound to glutathione–Sepharose 4B beads. The protein beads were reacted separately with cell extracts, washed extensively with
buffer (see Materials and Methods), and eluted stepwise with buffer containing 0.25 M KCl and then 0.5 M KCl. Eluates were desalted, concentrated,
resolved by SDS–PAGE, transferred to PVDF-membrane, and probed with PKR-specific antisera. (A) Western blot analysis of column eluates using
a polyclonal rabbit anti-PKR serum. FT lanes contain column flow-through material. (Lane 5) A aliquot of intact cell extract prior to reaction with
beads. (Lanes 1–4) Elutions from GST–beads. (Lanes 6–9) Elutions from GST–Tat beads. PKR-, the position of a 68-kDa band. (B) Western blot
analysis using a monoclonal anti-PKR serum. Elutions were performed with increasing salt (KCl) as indicated. Control lane contains whole extract.
Markers indicate radiolabeled molecular weight standards. (Lanes 3–5) GST–beads; (lanes 6–8) GST–Tax beads; (lanes 9–11) GST–Tat beads.
(C) Mapping of a subregion in Tat that binds PKR. Truncated versions of Tat protein (amino acids 20 to 72; amino acids 30–72, lanes 6–9; amino
acids 40–72, lanes 10–13) were expressed as fusion proteins with GST and affixed onto glutathione–Sepharose 4B beads. These beads were
reacted with cell extract (lane 1) followed by sequential washing and elutions. Samples were then analyzed by immunoblotting and detected using
rabbit polyclonal anti-PKR serum. FT, ‘‘flow-through’’ material from each of the beads. Prominent PKR signal is seen in all three of the flow-through
lanes (lanes 2, 6, and 10). A 68-kDa PKR band is detected in the 0.5 M eluate from the Tat 20–72 column. A higher exposure of the filter reveals
a 10-fold lighter band in the same elution from Tat 30–72 but no signal in the Tat 40–72 elution. The smaller 48 kDa PKR-reactive band (lanes 1,
2, 6, and 10) is a presumed breakdown product of the 68-kDa polypeptide. (D) GST–PKR and GST–6M fusion proteins, bound to Sepharose beads
(see Materials and Methods), were incubated with Tat 72 protein (1 mg) on ice for 30 min prior to extensive washing. Proteins were eluted by
boiling, separated by SDS–PAGE, and Tat detected by Western blotting.
Jeang, in preparation) replicate well, although the 1–72 (data not shown). We noted on repeated comparisons
that PKR was reproducibly retained by Tat (20–72)–virus is slightly slower than the 1–86 virus in T lympho-
cytes. Hence, we reasoned that residues 72 to 101 would Sepharose more avidly (0.5 M KCl eluate; Fig. 4C, lane
5) than by Tat (1–101)–Sepharose (0.25 M KCl eluate;likely be dispensible for functional interactions with PKR.
Indeed, we found that the PKR-interactive region in Tat Fig. 4A, lane 8; Fig. 4B, lane 10). One interpretation of
this result is that the presentation of amino acids 20– 72was contained within the 20–72 (Fig. 4C, lane 5) stretch.
Longer exposures revealed that Tat (30–72)–Sepharose in the context of GST–Tat 1–101 differs slightly from that
in the setting of GST–Tat 20–72.retained, in its 0.5 M eluate, approximately one-tenth the
amount of PKR seen for Tat (20–72)–Sepharose; while The direct binding of Tat 72 to PKR was also demon-
strated in reciprocal experiments in which the presenceno PKR was seen in Tat (40–72)–Sepharose samples
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of Tat 72 protein was assayed by Western blot after incu-
bation with purified PKR fused to glutathione-S-trans-
ferase (GST–PKR). Two forms of kinase fusion protein
were prepared, the full-length wild-type kinase (GST –
PKR), and a mutant kinase (GST–6M) which had lysine296
mutated to arginine (see under Materials and Methods).
GST–PKR is a fully functional kinase able to activate and
phosphorylate eIF2a (McMillan and Williams ‘‘unpub-
lished data’’), whereas GST–6M is unable to become
activated as the mutated lysine is essential for phosphate
transfer reactions (Chong et al., 1992; Hanks et al., 1988).
The bacterially produced fusion proteins were immobi-
lized on glutathione–Sepharose beads and purified prior
to the addition of Tat 72. Following incubation with Tat
72, the beads were washed and the proteins eluted off
the Sepharose beads and Tat 72 was detected by West-
ern blotting. Tat 72 bound equally well to both GST–PKR
and GST–6M (Fig. 4D) but was unable to bind to beads
alone or beads with GST attached, thus indicating that
PKR was mediating the binding of Tat protein.
PKR-mediated growth suppression in yeast is reversed
by HIV-1 Tat. We have previously reported the develop-
ment of a yeast system in which human PKR is expressed
by a GAL10-CYC1 hybrid promoter on the vector pRS313
(Chong et al., 1992). Strains of yeast transformed with
this plasmid and grown on galactose as a sole carbon
source exhibit a slow-growth phenotype due to the ex-
pression and activation of PKR. This results in phosphory-
lation of yeast eIF2a (Dever et al., 1993). This phenotype
FIG. 5. Effect of Tat on PKR function in yeast. (A) Strains bearingcan be rescued by coexpressing PKR with a mutant form
plasmid 86H were cotransformed with plasmids encoding either Tatof the yeast eIF2a (Ser51 r Ala), which can no longer
1–67, Tat 1–86, or vector alone, and expression was induced by incu-
be phosphorylated by PKR. Rescue of the slow-growth bation on plates containing galactose as the sole carbon source. All
phenotype is also possible by coexpressing PKR with plasmids were maintained by selection on synthetic medium lacking
uracil and histidine. (B) PKR was immunopurified using monoclonalthe amino terminus (amino acids 1–242) of PKR itself, a
antibody 71/10 from yeast whole cell extracts prepared from the strainsregion known to bind dsRNA (Chong et al., 1992). Accord-
86H/yex and 86H/Tat 1–67 (see Materials and Methods). Followingingly, we have used this yeast system to investigate the
extensive washing PKR was detected by Western blot. The arrows
role of Tat as an inhibitor of PKR. The advantage of using indicate the position of PKR. The other protein detected was IgG heavy
the yeast expression system is that, unlike mammalian chain from the monoclonal used to purify PKR.
cells, no endogenous PKR is present. Saccharomyces
cerevisiae is known to contain an eIF2a kinase, GCN2,
but its biology is markedly different from that of PKR in Tat was coexpressed with the kinase, reversion of the
slow-growth phenotype was observed (Fig. 5). Coexpres-that it is thought to be activated by uncharged tRNAs in
response to amino acid starvation (Dever et al., 1992; sion of Tat 86 had no effect on the slow-growth pheno-
type, in accord with its inability to inhibit PKR in vitro (Fig.Hinnebusch, 1988) although the exact activating species
is unknown. Consequently, we used this heterologous 5). This inhibition of PKR function in yeast was not due
to loss of PKR expression, as Western blots for PKRkinase expression system to study an in vivo interaction
between HIV-1 Tat and PKR. indicated similar levels of PKR in both 86H/yex- and 86H/
Tat67-expressing strains (Fig. 5B). The expression ofHIV-1 Tat cDNAs (encoding amino acids 1–67 and 1 –
86) were cloned under the control of the GAL10-CYC1 Tat72 in yeast gave the same phenotype as Tat67, i.e.,
reversion of slow growth.promoter in the vector pEMBLyex4 and transformed into
either the haploid yeast strain W303a or W303a already HIV Tat interacts with endogenous PKR in a HeLa cell
expression system. We wished to show a functional inter-expressing human PKR under GAL10-CYC1 control
(strain 86H). Expression of either Tat clone alone had no action between PKR and Tat protein in an in vivo context.
In order to demonstrate a functional interaction in mam-effect on growth (McMillan and Williams, unpublished
data). Expression of PKR resulted in the previously ob- malian cells, a rapidly inducible Tat expression system
was developed. HeLa cells were first stably transfectedserved slow-growth phenotype. However, when one exon
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FIG. 6. (A) Interaction of PKR with Tat 72 in vivo. Immunofluorescence analysis of dexamethasone-induced L3T4 expression of HeLa cells
conditionally expressing Tat. HeLa LTRT4/Tat72, LTRT4/Tat86, and LTRT4/Tat72AS cell lines were cultured for 18 hr in the presence (/DEXA) or
absence (0DEXA) of 2 mM dexamethasone. HeLa LTRT4/Tat72 cells were treated (/IFN) or not treated (0IFN) with 500 U/ml human interferona2
for 6 hr prior to dexamethasone addition. Cells were stained with a phycoerythrin-conjugated anti-L3T4 monoclonal antibody and cell surface
fluorescence of 104 cells was measured by flow cytometry. (B) Cell extracts from interferon- and dexamethasone-treated HeLa cell lines (LTRT4,
LTRT4/Tat72, and LTRT4/Tat86) were prepared under low salt conditions. Equal amounts of the extracts were then incubated with either PKR
monoclonal (lanes 1–5), Tat polyclonal (lanes 6–10), or Tat monoclonal (lanes 11–15) antibodies. Synthetic Tat 72 and bacterially expressed mutant
PKR (lys296 r arg) were used as controls. Following washing, immunocomplexes were analyzed for the presence of PKR by Western blot using a
rabbit polyclonal PKR antibody. (C) The levels of PKR protein in HeLa cells is unaffected by the dexamethosone-induced expression of Tat. Equal
amounts of whole cell extract (50 mg) were separated by SDS–PAGE, Western blotted, and PKR was detected using the monoclonal antibody
71/10.
with a Tat-dependent, cell-surface reporter construct, cell lines, PKR levels were induced by 6 hr pretreatment
with 500 U/ml human interferon a2 and Tat expressionpLTRL3T4hyg, which expresses the murine T-cell anti-
gen, L3T4, from a functional HIV-1 LTR containing the subsequently induced by the addition of 2 mM dexameth-
asone. Protein extracts from interferon- and dexametha-Tat-responsive region TAR. This cell line (HeLa LTRT4)
was subsequently transformed with the plasmids pMAM- sone-treated cells were treated with antibodies to either
PKR or Tat protein. Following extensive washing the im-Tat86, pMAMTat72, or pMAMTat72AS, which express Tat
86, Tat 72, or an antisense tat mRNA, respectively, from munocomplexes were Western blotted and analyzed for
the presence of PKR (Fig. 6B). Synthetic Tat 72 and re-the dexamethasone-inducible mouse mammary tumor vi-
rus LTR (Lee et al., 1981). Of the resultant cell lines, HeLa combinant, bacterially expressed PKR were used as con-
trols. PKR protein was present in all cell lines, as indi-LTRT4/Tat86 and LTRT4/Tat72 cells produced high levels
of surface-bound L3T4 after 18 hr of dexamethasone cated by immunoprecipitation with PKR monoclonal anti-
body (Fig. 6B, lanes 1–3 and lane 5). PKR was nottreatment (Fig. 6A). This system reports on the expres-
sion of functional Tat, as upregulation of L3T4 expression immunoprecipitated from either control cells or Tat 86-
expressing cells by the anti-Tat antibodies. However,was Tat-specific. Dexamethasone induction of HeLa
LTRT4/Tat72AS cells did not induce expression of sur- both the polyclonal and monoclonal Tat antibodies were
able to coprecipitate PKR from the Tat 72-expressing cellface-bound L3T4 (Fig. 6A), indicating that expression was
dependent on the synthesis of Tat protein. Prior inter- line (Fig. 6B, lanes 8 and 13). This immunoprecipitation
appears to be mediated by Tat 72, as recombinant PKRferon treatment was not observed to affect the dexameth-
asone induction of Tat expression in either HeLa LTRT4/ alone was not complexed by either of the Tat antibodies
(Fig. 6B, lanes 10 and 15). Longer exposures of the West-Tat72 or LTRT4/Tat86 cells (Fig. 6A).
To test the interaction between Tat and PKR in these ern blot indicated that a very low amount of PKR could
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and then the immunoprecipitate was visualized by immu-
noblotting analysis using a PKR-specific antiserum (Fig.
7C). In the last set, a 68-kDa protein consistent with the
molecular size of PKR was detected readily with the anti-
PKR serum (Fig. 7C, lane 2).
DISCUSSION
Our results provide direct evidence that an HIV-en-
coded protein can directly bind to an IFN-induced antivi-
ral protein and suggest a possible mechanism by which
HIV-1 may interact with IFN system. Other functional dif-
ferences have recently been described for the two forms
of Tat. Tat 86 has been reported to specifically downregu-
late expression from the MHC class I gene promotor
(Howcroft et al., 1993) as well as be required for TAR-
FIG. 7. Coimmunoprecipitation of Tat and PKR from cell-free extracts independent transactivation of the HIV envelope gene
of infected T lymphocytes. MT-2 cells infected with HIV-1 (NL4–3) were (Kim and Panganiban, 1993). The second coding exon of
harvested at a time when more than 70% showed light microscopy-
Tat also plays a role in the transactivation of integratedvisible cytopathic effects from infection. (A) Western blot analysis of
LTRs (Jeang et al., 1993b). However, while single exontotal cell lysate using HIV-1 hyperimmune patient serum. (Lane 1) Mock-
infected MT-2 cells; (lane 2) MT-2 infected with HIV-1 (NL4–3). p55 Tat (72 amino acids) is fully functional for transactivation
and p24 indicate Gag gene products. (B) A parallel set of infected cells of nonintegrated LTRs (Rosen, 1991), no specific function
was radiolabeled with [35S]methionine and [35S]cysteine and immuno- has been described to it that is distinct from that of two-
precipitated using a polyclonal rat anti-Tat serum (Yamamoto et al.,
exon Tat. The work presented here indicates that Tat 721988). The position of a doublet that migrates with an approximate size
can act as a specific antagonist to both PKR activationof 14 kDa is indicated (0Tat). The lower band is presumed to be
a degradation product of Tat. (C) Western blot analysis of anti-Tat and substrate phosphorylation. The latter activity oc-
immunoprecipitate from mock-infected (lane 1) and infected (lane 2) curred in manner independent of the inhibition of activa-
(but not radiolabeled) cells. Immunoprecipitates were resolved in a tion. This antagonistic activity can be shown to occur in
10% SDS–polyacrylamide gel, transferred to PVDF-membrane (Milli-
vitro and in yeast, although it remains to be demonstratedpore), and reacted with polyclonal rabbit anti-PKR serum (Huang et al.,
during HIV infection.1994).
Stable complexes between Tat 72 and PKR could be
detected both in vitro and in vivo, indicating that inhibition
of PKR function appears to be mediated via a direct pro-be immunoprecipitated from the Tat 86-expressing cells.
This is consistent with Tat 86 being a substrate of PKR tein–protein interaction. Thus the inhibition of PKR auto-
phosphorylation by Tat 72 could be due to the hindranceand being readily released by PKR, as has been pre-
viously observed for eIF2a (Hovanessian, 1989). of conformational changes that may be required for PKR
activation. The region of Tat required for interaction withFinally, to rule out the possibility that the levels of PKR
were affected by the various treatments, equal amounts PKR was mapped to amino acids 20–72 (Fig. 4). Because
Tat 40–72 contains the entire RNA-binding domain ofof whole cell extract (50 mg) were immunoblotted and
PKR was detected using the PKR monoclonal antibody Tat but this moiety did not bind PKR, our results are
compatible with direct Tat–PKR association as opposed71/10 (Fig. 6C). As expected, PKR levels were observed
to increase upon treatment of cells with interferon. How- to an indirect interaction tethered through double-
stranded RNA.ever, neither the expression of Tat nor the dexametha-
sone treatment of cells was observed to affect the levels The binding site(s) of Tat 72 within PKR appears to be
on or near the site of eIF2a binding, as preincubation ofof PKR.
Tat associates with PKR in HIV-1-infected lymphocytes. PKR with eIF2 blocks Tat binding (N. M. J. McMillan and
B. R. G. Williams, unpublished observations). This sug-To determine directly whether Tat and PKR interact within
T lymphocytes, we analyzed cell-free extracts from HIV-1 gests that Tat is acting as a substrate analogue for PKR
and blocks substrate phosphorylation in this manner.(pNL4-3)-infected MT-2 cells for a coimmunoprecipitable
Tat –PKR complex. Infected cells were divided into three This hypothesis is further supported by the fact that Tat
86 is phosphorylated by PKR in vitro. However, the possi-parallel sets. One was analyzed in order to document
viral-specific antigens as a measurement of infection bility that eIF2 changes the conformation of PKR and thus
obscures the Tat binding site(s) cannot be discounted.(Fig. 7A). A second set was radiolabeled with [35S]-
methionine and [35S]cysteine and immunoprecipitated Furthermore, PKR activation, which is thought to occur
via intermolecular phosphorylation, could be inhibited bywith anti-Tat serum to verify recovery of Tat protein (Fig.
7B). A third was immunoprecipitated first with anti-Tat interfering with PKR–PKR interaction. A known example
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of a PKR inhibitor which acts as a substrate analogue is it may be possible to design peptide inhibitors of Tat
which could prove useful in testing this hypothesis.the K3L gene product of Vaccinia virus (Beattie et al.,
1991). K3L shares 28% identity with the a-subunit of eIF2
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